We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nycomed to Distribute Palladium-103 Seeds

By MedImaging staff writers
Posted on 02 Oct 2000
Nycomed Amersham plc (Little Chalfont, U.K.), a leading supplier of iodine brachytherapy seeds for the treatment of prostate cancer, has entered into an agreement with Theragenics Corp. More...
(Buford, GA, USA) for the distribution of Theragenics' palladium-103 brachytherapy seeds.

The palladium-103, rice-sized seeds are used for the treatment of localized prostate cancer in a one-time minimally invasive procedure. A capsule containing 40-100 seeds, called TheraSeed, is implanted in the prostate. Theragenics is involved in research on other treatment applications for palladium-103, including restenosis and macular degeneration. Nycomed currently markets OncoSeed, iodine-125 brachytherapy seeds distributed with Rapid Strand in a rigid, absorbable suture material, permitting even placement of the seeds and holding them in position while preventing migration to other body sites.

With this expanded portfolio, we will be better able to meet the needs of the market and provide brachytherapy seeds to all patients who will benefit from this minimally invasive high efficacy procedure for treating prostate cancer, said John Jeans, president of Nycomed Amersham Therapy Products.



Related Links:
Nycomed Amersham
Theragenics Corp.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.